Navigation auf


UZH Innovation Hub

Stefan Kleiser

A non-invasive device that monitors oxygen levels in the brains of preterm infants

Stefan Kleiser and Team
Photo: Daniel Ostojic, Alexander Nitsch, Dr. Stefan Kleiser, Prof. Dr. Martin Wolf (left to right)

Stefan Kleiser joined the Entrepreneur Fellowship program to work on translating a novel oximeter to clinical use. Based on a highly precise research tissue oximeter, he and his team developed a medical device improving intensive care by avoiding oxygen undersupply and brain damage. The translation of OxyPrem has be focused on user needs and industrialized manufacturing, in close linkage and cooperation with later customers. To date, the team has developed a product that is about to be CE-certified. Oxyprem’s vision is to contribute to a decrease in child mortality and severe life-long brain damage in survivors.

Oxyprem is currently supported by Uniscientia foundation, Venture Kick, and Wyss Zurich. They received the CE-certification for their product in summer 2019.

Affiliation: Prof. Dr. Martin Wolf

Start date: 02/2018


  • Stefan Kleiser co-founded the UZH Spin-off OxyPrem AG in 2018

  • OxyPrem enters WYSS Zurich in 2019

  • OxyPrem wins Venture Kick in 2019

  • OxyPrem was awarded the Seal of Excellence by the European Union's Accelerator program (SME Instrument phase II) in 2020

  • OxyPrem has obtained CHF 2.2 milion from SERI-funded EIC Accelerator grant in 2022

  • OxyPrem wins 2nd place at SWISS EXCELLENCE AWARD in 2022

Weiterführende Informationen


Dr. Stefan Kleiser has successfully completed the UZH Entrepreneur Fellowship in August 2019.


Dr. Stefan Kleiser
+49 160 929 339 76


Alexander Nitsch
Business Development 
+41 76 263 87 31


OxyPrem AG
c/o Universität Zürich
Klinik für Neonatologie
Frauenklinikstrasse 10 
8091 Zürich (Switzerland)